Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0 T MR spectroscopy

European Journal of Radiology

Volumn 75, Issue 2, 2010, Pages

  Van Werven, J R ^a   Schreuder, T C M A ^b   Nederveen, A J ^a   Lavini, C ^a   Jansen, P L M ^a   Stoker, J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fatty acids; Fatty liver; Magnetic resonance spectroscopy; Unsaturated

Indexed keywords

DISEASES; FATTY ACIDS; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATASES;

ALKALINE PHOSPHATASE; FATTY LIVER; METABOLIC PARAMETERS; METABOLIC SYNDROMES; NON-ALCOHOLIC FATTY LIVER DISEASE; NONINVASIVE TECHNIQUE; TYPE 2 DIABETES MELLITUS; UNSATURATED;

UNSATURATED FATTY ACIDS;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; LIVER ENZYME; TRIACYLGLYCEROL; UNSATURATED FATTY ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER FUNCTION; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 77955851425     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.12.033     Document Type: Article

References (56)

1. Angulo P. Nonalcoholic fatty liver disease. N Eng J Med 2002;346:1221-31.
2. Kim WR, Brown Jr RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: Summary of a workshop. Hepatology 2002;36:227-42.
3. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Sem Liver Dis 2001;21:17-26.
4. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
5. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An expanding clinical entity. Gastroenterology 1994;107:1103-9.
6. Lee RG. Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol 1989;20:594-8.
7. Powell EE, CooksleyWG,Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
8. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with crypotogenic cirrhosis: A case-control study. Hepatology 2000;32:689-92.
9. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. AJP-Endocrinol Metab 2005;288:E462-8.
10. Fishbein M, Castro F, Cheruku S, et al. Hepatic MRI for fat quantification. J Clin Gastroenterol 2005;39:619-25.
11. Picardi A, Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: A first message should pass. Am J Gastroenterol 2008;103:3036-8.
12. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
13. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
14. Merriman RB, Farrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected non-alcoholic fatty liver disease. Hepatology 2006;44:874-80.
15. Mathiesen UL, Franzen LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002;34:516-22.
16. Siegelman E, Rosen M. Imaging of hepatic steatosis. Semin Liver Dis 2001;21:71-80.
17. Jackobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver for contrast-enhanced helical CT. AJR Am J Roentgenol 1998;171:659-64.
18. Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study. BMC Gastroenterology 2005;5:4.
19. Limanond P, Raman SS, Lassman C, et al. Macrovesicular hepatic steatosis in living related liver donors: Correlation between CT and histologic findings. Radiology 2004;230:276-80.
20. Ataseven H, Yildirim MH, Yalniz M, Bahcecioglu IH, Celebi S, Ozercan IH. The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2005;68:221-5.
21. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
22. Schuchmann S, Wiegel C, Albrecht L, et al. Non-invasive quantification of hepatic fat fraction by fast 1.0, 1.5, 3.0 T MR imaging. Eur J Radiol 2007;62:416-22.
23. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior-knowledge. J Magn Reson 1997;129:35-43.
24. van Werven JR, Hoogduin JM, Nederveen AJ, et al. Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat. J Magn Reson Imag 2009;30:444-8.
25. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: Is biopsy necessary? Eur J Gastroenterol 2003;15:539-43.
26. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11:37-54.
27. Fischbach F, Bruhn H. Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: A review. Liver Int 2008;28:297-307.
28. Longo R, Pollesello P, Ricci C, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imag 1995;5:281-5.
29. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by 1H spectroscopy: Validation in vivo. Am J Physiol Endocrinol Metab 1999;276:E977-89.
30. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Hendriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imag 1994;12:487-95.
31. Belford R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng J Med 2006;355:2297-307.
32. 1Hlocalized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993;8:297-302. (Pubitemid 24079682)
33. Fischbach F, Schimmer T, Thormann M, Freund T, Ricke J, Bruhn H. Quantitative proton magnetic resonance spectroscopy of the normal liver and malignant lesions at 3.0 Tesla. Eur Radiol 2008;18:2549-58.
34. Ishii M, Yoshioka Y, Ishida W, et al. Liver fat content measured by magnetic resonance spectroscopy at 3.0 Tesla independently correlates with plasminogen activator-1 and body mass index in type 2 diabetic subjects. Tohoku J Exp Med 2005;206:23-30.
35. Corbin IR, Furth EE, Pickup S, Siegelman ES, Delikatny EJ. In vivo assessment of hepatic triglycerides in murine non-alcoholic fatty liver disease using magnetic resonance spectroscopy. Biochim Biophys Acta 2009;1791:757-63.
36. Ren J, Dimitrov I, Dean Sherry A, Malloy CR. Composition of adipose tissue and marrow fat in humans by 1H-NMR at 7 Tesla. J Lipid Res 2008;49:2055-62.
37. Velan SS, Said N, Durst C, et al. Distinct patterns of fat metabolism in skeletal muscle of normal-weight, overweight, and obese humans. AJP-Regul Intergr Comp Physiol 2008;295:R1060-5.
38. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with NAFLD: A pilot study. Aliment Pharmacol Ther 2006;23:1143-51.
39. Murase T, Aoki M, Tokimitsu I. Supplementation with alfa-linolenic acidrich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of beta-oxidation in Zucker fatty rats. Biochim Biophys Acta 2005;1733:224-31.
40. Alwayn IP, Andersson C, Zauscher B, Gura K, Nose V, Pruder M. Omega-3 fatty acids improve hepatic steatosis in a murine model: Potential implications for the marginal steatotic liver donor. Transplantation 2005;79:606-8.
41. Alwayn IP, Gura K, Nose V, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of non-alcoholic fatty liver disease. Pediatr Res 2005;57:445-52.
42. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with non-alcoholic fatty liver disease. Dig Liver Dis 2008;40:194-9.
43. El-Badry AM, Graf R, Clavien PA. Omega 3-omega 6: What is right for the liver? J Hepatol 2007;47:718-25.
44. Song BJ, Moon KH, Olsson NU, Salem Jr N. Prevention of alcoholic fatty liver and mitochondrial dysfunction in the rat by long-chain polyunsaturated fatty acids. J Hepatol 2008;49:262-73.
45. de Koning L, Merchant AT, Poque J, Anand SS. Waist circumference and waistto- hip ratio as predictors of cardiovascular events: Meta-analysis of prospective studies. Eur Heart J 2007;28:850-6.
46. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification. Geneva: World Health Organization; 1999b.
47. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7.
48. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12:142-52.
49. de Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: Preliminary results. Radiology 2004;230:652-9.
50. Yki-Järvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 2005;5:287-95.
51. Roden M. Mechanisms of Disease: Hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. N Clin Pract Endocrinol Metab 2006;2:335-48.
52. Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529-39.
53. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008;52:885-97.
54. Wanless I, Lentz J. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
55. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-9.
56. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterology Hepatol 2004;19:854-8.